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Abstract 
Thyroperoxidase (TPO) is the enzyme that synthesizes thyroid hormones (THs). TPO inhibition by 
chemicals can result in decreased TH levels and developmental neurotoxicity, and therefore 
identification of TPO inhibition is of high relevance in safety evaluation of chemicals. In the present 
study, we developed two global quantitative structure-activity relationship (QSAR) models for TPO 
inhibition in vitro. Rigorous cross- and blinded external validations demonstrated that the first 
model, QSAR1, built from a training set of 877 chemicals, was robust and highly predictive with 
balanced accuracies of 80.6% (SD = 4.6%) and 85.3%, respectively. The external validation test set 
was subsequently merged with the training set to constitute a larger training set totaling 1,519 
chemicals for a second model, QSAR2, which underwent robust cross-validation with a balanced 
accuracy of 82.7% (SD = 2.2%). An analysis of QSAR2 identified the ten most discriminating structural 
features for TPO inhibition and non-inhibition, respectively. Both models were used to screen 72,524 
REACH substances and 32,197 U.S. EPA substances, and QSAR2 with the expanded training set had 
an approximately 10% larger coverages compared to QSAR1. Of the substances predicted within 
QSAR2’s applicability domain, 8,790 (19.3%) REACH substances and 7,166 (19.0%) U.S. EPA 
substances, respectively, were predicted to be TPO inhibitors. A case study on butyl hydroxyanisole 
(BHA), which is extensively used as an antioxidant, was included to exemplify how predictions from 
the developed QSAR2 model may aid in elucidating the modes of action in adverse outcomes of 
chemicals. Overall, predictions from QSAR2 can for example be used in priority setting of chemicals 
and in read-across cases or weight-of-evidence assessments. 
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1. Introduction 
Thyroid hormones (THs) participate in multiple biological processes from early development and 
throughout adulthood [1–3]. In the fetus and neonate, THs play an essential role in 
neurodevelopment [4], where they are involved in neuron differentiation, proliferation and 
migration, dendritic branching and synaptogenesis, and myelination [1,5]. In early gestation, the 
fetus depends entirely on maternally-derived THs until the fetal thyroid gland becomes functional at 
approximately gestational week 12 in humans and gestational day 17-18 in rats [1,6,7]. Maternal THs 
continue to contribute to fetal TH levels throughout gestation in both humans and rats [1,6]. Studies 
have shown that even a moderate and transient decrease in maternal TH levels during pregnancy is 
associated with permanent adverse neurological changes in the offspring [8]. In animal models and 
humans altered cognition, socialization and motor function as well as hearing loss have been 
observed following moderate to severe hypothyroidism [6,9–17]. Even low levels of TH insufficiency 
during fetal development may result in measurable IQ deficits in children [9,13–18]. In adulthood, 
dysregulated TH levels can give reversible clinical symptoms of hypo- or hyperthyroidism [8] and are 
correlated with pathological processes involved in adverse outcomes such as cancer, obesity and 
type II diabetes mellitus [19,20].  
Humans are exposed to tens of thousands of man-made chemicals through food, drugs, air, water 
and consumer products [21–24]. Large data gaps exist for most of these xenobiotics on their 
potential thyroid disrupting properties [25]. Xenobiotics can disturb TH homeostasis through many 
different mechanisms, including altered TH synthesis, transport, metabolism, and thyroid hormone 
receptor activation as well as disruption of the hypothalamus-pituitary-thyroid axis [10,25–28]. The 
same xenobiotic may act through more than one mechanism [25]. Because of the severity of the 
adverse effects that can be expected from chemical disruption of thyroid homeostasis, especially 
during early development, there is a need to develop a strategy for the identification and testing of 
thyroid-active compounds. As a step towards replacing expensive and time-consuming whole animal 
studies with alternative methods in chemical risk assessments, the Organisation for Economic Co-
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operation and Development (OECD) launched a new program on the development of Adverse 
Outcome Pathways (AOPs) in 2012 [29]. An AOP describes the sequential chain of causally linked 
events at different levels of biological organization starting from a so-called molecular initiating 
event (MIE) going through a number of downstream linked key events (KEs), and ends at an adverse 
health or ecotoxicological effect [29,30]. According to the OECD, AOPs are the central element of a 
toxicological knowledge framework to support chemical risk assessment based on mechanistic 
reasoning. AOPs can help industry and regulators use results from alternative methods, such as in 
vitro and in silico methods, in chemical risk assessments [31], e.g. by applying the AOP in OECDs 
Integrated Approaches to Testing Assessment (IATA) context [29,32,33]. Multiple thyroid-related 
AOPs have been suggested [34,35]. One AOP under development determined to have a strong 
overall weight-of-evidence (WoE) describes a series of linked events from the MIE, thyroperoxidase 
(TPO) inhibition, leading to hypothyroxinemia, and resulting in altered neurodevelopment and 
neurological dysfunction in the offspring [36, see also 4 and 25]. TPO is a heme-containing 
multifunction enzyme essential in TH synthesis [37,38]. Recently, a high-throughput screening (HTS) 
in vitro assay for TPO inhibition was developed by the U.S. Environmental Protection Agency (EPA) 
National Center for Computational Toxicology (NCCT) [39] and used to screen 1,126 ToxCast Phase I 
and II chemicals including structurally diverse environmental chemicals and failed drugs [34,40,41]. 
The assay is based on microsomes from rat thyroid tissue and requires the amount from 
approximately one rat to assess quantitative TPO inhibition of 1.5 chemicals [39]. An additional set 
of 771 ToxCast chemicals (known as the ‘Endocrine 1000’ or ‘E1K´ set) [41,42] was subsequently 
screened in the same HTS TPO inhibition assay (Simmons et al., in prep).  
The goal of the present study was to use the ToxCast data to develop in silico models, and apply the 
models to large inventories of man-made chemicals to predict their potential to inhibit TPO. For this 
purpose, we first used experimental TPO inhibition results for 1,126 ToxCast Phase I and II chemicals 
to prepare a training set of 877 chemicals, which was then used to train and cross-validate a global 
binary Quantitative Structure-Activity Relationship (QSAR) model. QSARs are mathematical models 
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that relate chemical structure descriptors with an experimental continuous (e.g. EC50) or categorical 
(e.g. positive/negative) activity. Once established, these in silico models can be used as a non-testing 
approach to predict the activities of untested chemical structures (an introduction to QSAR can e.g. 
be found in [43] and [44]). The E1K dataset was used to prepare a test set of 646 chemicals, which 
was applied to externally validate the QSAR model. Next, the test set was merged with the training 
set to form a larger training set of 1,519 chemicals, which was subsequently used for training and 
cross-validating a second QSAR model. An analysis of the structural features in the second QSAR 
model was performed to identify the top features that discriminated TPO inhibitors from non-
inhibitors. Both QSAR models were used to screen two large EU and U.S. chemical inventories 
containing man-made substances potentially present in e.g. the environment and consumer 
products for their possible TPO inhibition activity. The screened EU inventory consist of 72,524 
REACH pre-registered substances (PRS) extracted from the online Danish (Q)SAR Database structure 
set [45,46]. Briefly, REACH pre-registration concerns existing substances that companies plan to 
register under REACH as so-called phase-in substances and the full PRS list contains a total of 
145,299 unique substances/entries [47]. The U.S. inventory was originally curated by the U.S. EPA as 
a part of the CERAPP project [48] and contains 32,464 unique structures to which humans are 
potentially exposed. The structures were curated from sources such as the ACToR CPCat database 
[21], the DSSTox database [49], the Canadian Domestic Substances List, the Endocrine Disruption 
Screening Program set and EPI Suite training and test sets [41,42,48]. Predictions from these 
screenings will inform a tiered approach to prioritize possible thyroid modulating chemicals for 
further evaluation and could be used, together with relevant AOP(s), in IATA WoE assessments 
[29,33,50]. We also conducted a case study to highlight how the developed QSAR models for TPO 
inhibition can support hypotheses regarding the mode of action for chemical-induced adverse 
outcomes observed in in vivo studies. 
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2. Materials and Methods 
2.1 Experimental Datasets 
We used two datasets provided by U.S. EPA NCCT with chemical structure information and HTS 
screening results for TPO inhibition in vitro to train and validate two QSAR models. The chemicals 
screened contained diverse chemical structures including environmental and industrial chemicals, as 
well as some failed drugs [41]. The chemicals in both datasets were not selected specifically for this 
project or based on suspected TPO inhibition activity, and the original datasets include internal 
replicated samples. The experimental results consisted of data from the HTS Amplex®UltraRed-
thyroperoxidase (AUR-TPO) in vitro assay [39], which had further undergone a selectivity filtering 
procedure to identify potentially false positive results due to non-specific activity decrease in the 
AUR-TPO assay [34]. Briefly, all chemical structures were initially screened at a single, high 
concentration (~87.5µM). The chemicals associated with 20% or greater decreases in maximal TPO 
activity were subsequently screened for possible concentration-response. The concentration-
response data were processed as described previously using the ToxCast data pipeline whereby each 
chemical was assigned a ‘hit-call’ of 1 if active in AUR-TPO, or a ‘hit-call’ of 0 if inactive in AUR-TPO 
[51]. Actives in the AUR-TPO assay were further processed through a selectivity filtering algorithm, 
which integrates results from cytotoxicity and luciferase inhibition assays to identify possible non-
specific positive results in the AUR-TPO assay [34]. The chemical structures, assays, data analysis and 
selectivity filtering procedure have been described in more details previously [34,39,40,51]. We 
classified the chemicals into three categories (Figure 1): 1) chemicals that had a <20% activity 
decrease in the single, high concentration screening or had been assigned a ‘hit-call’ of 0 in the 
concentration-response AUR-TPO screening were classified as inactive in this assay; 2) chemicals 
with a ‘hit-call’ of 1 in AUR-TPO and a selectivity score greater than 1 were classified as active for 
TPO inhibition; and 3) chemicals with a ‘hit-call’ of 1 in AUR-TPO but with a selectivity score of 1 or 
less were classified as inconclusive for TPO inhibition.  
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The first dataset provided to the QSAR model developers at the Technical University of Denmark 
National Food Institute (DTU Food) consisted of structure information and experimental results for 
1,126 ToxCast Phase I and II chemicals [34,40,41], including replicates, and was used for preparing a 
training set referred to as training set 1 (Figure 1). The second E1K dataset of an additional 771 
chemicals from ToxCast [41,42], initially containing only structural information, was used for 
preparing a test set of 646 chemicals for external validation of the selected QSAR model built from 
training set 1 (see 2.3) (Figure 1). After determining the external validation statistics, the 
experimental results of the test set structures were made available to the model developers at DTU 
Food. The test set and training set 1 were then merged to form a second, larger training set referred 
to as training set 2 (Figure 2).  
2.2 Structure Preparation 
All chemical structures in the two U.S. EPA NCCT provided datasets had previously undergone an 
extensive quality control and structure curation procedure as part of the ToxCast program [41,52]. 
The QSAR software applied in this study handles organic chemical structures with an unambiguous 
2D structure. We apply an overall definition of structures acceptable for QSAR processing in all our 
in-house QSAR software [45,46], as structures:  
 containing at least two C atoms 
 containing only the atoms H, Li, B, C, N, O, F, Na, Mg, Si, P, S, Cl, K, Ca, Br, and/or I; and, 
 that are not mixtures consisting of two or more organic components  
The structures that did not fulfill these criteria were removed from the two datasets. Further 
processing of the structural information included stripping off ions and neutralization of the organic 
parent structures, i.e. all structures were used in their non-ionized form (Figure 1).  
Next, identical QSAR-ready structures within the first dataset were identified and their assigned 
experimental results were compared. For identical structures with concordant activities, only one of 
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the structures was kept. If a group of identical structures had discrepant activities then the whole 
group was removed from the dataset. Next, structures with inconclusive experimental results, i.e. 
‘hit-call’ of 1 in AUR-TPO and a selectivity score of 1 or less, were removed and the dataset now 
constituted training set 1 (Figure 1). The same duplicates removal procedure was performed by U.S. 
EPA NCCT scientists on the DTU Food experimentally-blinded E1K set, which then constituted the 
test set (Figure 1). Some of the QSAR-ready structures in the test set were identical to structures in 
training set 1 and were therefore excluded from the external validation. When the test set 
experimental results were made available to DTU Food, and training set 2 was prepared by merging 
the test set and training set 1 (Figure 2), the experimental results of the identified structural 
duplicates were compared. Again, if they had concordant experimental result only one of the 
structures was kept, while all the structures were removed in case of disagreement between the 
experimental results. 
2.3 QSAR Modeling and Selection  
We used the commercial software Leadscope® Predictive Data Miner (LPDM), a component of 
Leadscope® Enterprise Server version 3.2.4 [53], to build the QSAR models. Briefly, for each chemical 
structure in a training set LPDM automatically performs a systematic sub-structural analysis using a 
template library of more than 27,000 predefined structural features and calculates nine molecular 
descriptors (AlogP, Hydrogen Bond Acceptors and Donors, Lipinski Score, Molecular Weight, Parent 
Atom Number, Parent Molecular Weight, Polar Surface Area, Rotatable Bonds) [54]. The structural 
features and molecular descriptors are included in a default descriptor set. In addition, the user may 
call a functionality in LPDM to generate and add new training set-dependent structural features 
(scaffolds) to the descriptor set. The pre-defined structural features, added scaffolds and numeric 
molecular descriptors are included in an initial descriptor set. From the initial descriptor set, an 
automatic descriptor selection procedure in LPDM selects the top 30% descriptors according to 
Yates X2-test for a binary response variable. For the current training set 1 and 2 with binary 
responses, predictive models were built using partial logistic regression (PLR) with further selection 
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of descriptors in an iterative procedure, and selection of the optimum number of PLR factors based 
on least predictive residual sum of squares. LPDM has the option of building composite models, a 
type of ensemble model [55], for training sets with an imbalanced distribution of actives and 
inactives. With this option a number of sub-models are created by specifying the desired ratio of 
actives to inactives per sub-model training set, so that each of the sub-models contains the smaller 
class and a sample of the bigger class. The positive prediction probability (see 2.4) for a query 
chemical from a composite model is defined as the average of the positive prediction probabilities of 
all sub-models having the test chemical in the applicability domain (AD) [56]. This is in contrast to 
single models where the entire training set is used to train one single model. 
Multiple modeling approaches were applied in LPDM to build seven predictive models for TPO 
inhibition first using training set 1 (Figure 2):  
1) single (i.e., non-composite) 
2) single with scaffolds 
3) single with scaffolds and a reduced set of structural features 
4) composite 
5) composite with scaffolds 
6) composite with scaffolds and a reduced set of structural features 
7) composite model combining model 3 and the sub-models from model 6  
 
In 1 and 4, the descriptors were selected among the default descriptors, i.e. the molecular 
descriptors and the predefined structural features, and used to build a single model and a composite 
model, respectively. Next, scaffolds were generated in LPDM for the training set structures and 
added to the initial descriptor set, which subsequently was used for descriptor selection for models 
2 and 5. In models 3 and 6, the scaffold-enriched descriptor set was reduced using a built-in function 
in LPDM (i.e., ‘Remove most features – (removes less similar features)’) that removed certain similar 
structural features before the descriptor selection. This step was employed to achieve a higher-
quality set of fewer structural features, eliminate highly similar or redundant ones, and reduce the 
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risk of overfitting. In model 7, the single model 3 and the sub-models from composite model 6 were 
combined to constitute a new composite model with equal weight of all its sub-models.  
All seven models underwent a ten times two-fold cross-validation by the LPDM algorithm. The 
algorithm transfers knowledge of the selected descriptor set from the parent model when building 
the cross-validation models, and we therefore do not use it for our measures of absolute predictive 
performance, but only to guide relative performance-based selection between the seven preliminary 
models. Among the seven predictive models built from training set 1, we selected the model with 
the highest performance from the LPDM cross-validation for further validation and screening studies 
(Figure 2). The selected model, called QSAR1, was then closed for further development. 
2.4 Applicability Domain Definition 
The definition of the AD applied in this project consists of two components: 1) the definition of a 
structural domain in LPDM, and 2) a DTU Food in-house class probability refinement on the output 
from LPDM:  
1) For a test compound to be within LPDM’s structural domain it was required that: all molecular 
descriptors used in the model could be calculated, it contained at least one structural feature used in 
the model, and it had at least 30% Tanimoto similarity with a training set compound [56]. The 30% 
Tanimoto similarity was a default cut-off in the LPDM software. For a test compound outside this 
structural domain no prediction call (active/inactive) was generated by LPDM. For test compounds 
within the LPDM structural domain, a positive prediction probability, p, between 0 and 1, was given 
together with the prediction call; actives having a p ≥ 0.5 and inactives having a p < 0.5 [56].  
2) To exclude less reliable predictions, i.e. those with a positive prediction probability close to the 
cutoff p = 0.5, we required p ≥ 0.7 for active prediction calls and p ≤ 0.3 for inactive prediction calls. 
Predictions within the LPDM structural domain but with an associated positive prediction probability 
in the interval 0.3 to 0.7 were thus defined as outside of the AD and excluded from the statistical 
analyses. 
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2.5 Validation of the Models  
Next, the closed QSAR1 model underwent an external validation blinded to DTU Food using the test 
set to evaluate its predictive performance (Figure 2). U.S. EPA NCCT compared the DTU Food 
generated test set prediction calls within the AD (see 2.4) with the corresponding experimental 
results and calculated sensitivity, specificity, balanced accuracy and coverage. Sensitivity is the 
percentage of experimental actives correctly predicted, specificity is the percentage of the 
experimental inactives correctly predicted, and balanced accuracy is the average of the sensitivity 
and specificity [57]. The coverage is the proportion of test set compounds that had predictions 
within the model’s AD.  
The assigned experimental activities for the test set were then made available to DTU Food, who 
merged the test set with training set 1 to constitute the larger training set 2 (see 2.2). Training set 2 
was used to build seven predictive models using the same modeling and LPDM cross-validation 
approaches described for training set 1 in section 2.3, and of these the best performing model was 
selected (Figure 2). The selected model, called QSAR2, was closed for further development. 
As described above, the LPDM cross-validation algorithm was, due to the issue with transfer of 
knowledge to the cross-validation models, only used to guide the selection of the best performing 
model among the seven models built from training set 1 and 2, respectively. The two selected and 
closed models, QSAR1 and QSAR2, were each subsequently subjected to a DTU Food in-house five 
times two-fold stratified cross-validation procedure to further estimate their robustness and 
predictive performance (Figure 2). This was done by randomly removing 50% of the structures from 
the training set, preserving the ratio of actives and inactives. Then a cross-validation model was built 
on the reduced training set using the same modeling approach as the full, parent model, but without 
transferring any established information such as selected descriptors from the parent model. The 
cross-validation model was applied to predict the 50% of the training set that had been removed. 
Likewise, a cross-validation model was made using the removed 50% of the training set, and this 
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model was used to predict the remaining 50%. This procedure was performed five times resulting in 
ten cross-validation models. Sensitivity, specificity and balanced accuracy were calculated for the in-
AD predictions for each of the ten cross-validation models, and the mean and standard deviation 
(SD) were computed to give overall statistical measures of the predictive performance and 
robustness of the parent model based on the full-training set. The coverage, i.e. the mean 
percentage of how many of the predicted substances that had predictions within the AD of the ten 
cross-validation models, was also calculated. 
2.6 Structural Features in QSAR2 
To identify structural features in QSAR2 related to TPO inhibition or non-inhibition, respectively, all 
features in the model were sorted in descending order by: 
               
where n is the number of training set 2 structures containing the given feature, and   is the mean 
TPO inhibition experimental activity (1 for actives and 0 for inactives) of the n training set structures.  
With this metric the QSAR2 structural features that discriminate well between the two classes, i.e. 
actives and inactives, and are contained in the largest number of training set 2 structures are given 
the highest ranking. Based on this sorting, the top ten structural features with an   ≥ 0.8, i.e. 
structural features associated with activity, and an   ≤ 0.02, i.e. structural features associated with 
inactivity, respectively, were identified (Figure 2). The cutoff of   ≤ 0.02 was chosen instead of 0.2, 
which would have been symmetric to the   ≥ 0.8 cutoff for activity associated structural features, 
due to the larger proportion of inactive structures in the training set.  
2.7 Screening Large Chemical Inventories 
The structures in the REACH-PRS inventory were originally curated from deliverable 3.4 of the 
OpenTox EU project and had previously been processed through the structure preparation steps 
described in section 2.2 [58]. The 72,524 QSAR-ready REACH-PRS structures included structural 
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duplicates, and the REACH-PRS set thus contained a total of 60,281 unique structures (Figure 2). The 
U.S. EPA inventory was also previously processed through the structure preparation steps described 
in section 2.2 and 32,197 unique QSAR-ready structures remained. Both the REACH-PRS set and the 
U.S. EPA set were screened through the QSAR1 and QSAR2 TPO inhibition models to identify 
substances with the potential to inhibit TPO. We applied both QSAR1 and QSAR2 to be able to assess 
the effect of adding the test set structures to training set 2 with regard to their coverages and the 
prevalence of predicted TPO inhibitors in the two models. While QSAR2 is likely to provide a better 
coverage of the inventories, the lack of an external validation of QSAR2 may for some purposes 
suggest that QSAR1 is a more appropriate tool. 
The overlaps in substances as well as unique structures between U.S. EPA and REACH-PRS were 
identified (Figure 2). The proportion of the QSAR-predicted U.S. EPA and REACH-PRS substances 
within the AD of QSAR1 and QSAR2 and the activity distributions of the predictions were calculated.  
3. Results and Discussion 
This is to our knowledge the first study to develop global binary QSAR models for TPO inhibition and 
apply them to predict two large and structurally diverse chemical inventories containing man-made 
substances for their TPO inhibiting potential.  
3.1 The Training and Test Sets 
The number of QSAR-ready structures and the distribution of active and inactive experimental 
results in training set 1, the test set and training set 2 are summarized in Table 1. The numbers given 
in the table reflect the situation after removing structures that were either unsuited for QSAR 
processing in the applied software, structural duplicates or had inconclusive experimental results. In 
training set 1 this resulted in the removal of 72 structures due to structural QSAR criteria, i.e. 
structures not acceptable for QSAR processing, 21 due to structural duplicates (four of these due to 
conflicting experimental results), and 156 due to inconclusive experimental results; in total 249 out 
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of the 1,126 initial structure entries. In the external validation test set , a total of 125 out of the 771 
initial E1K structure entries were removed; 14 due to structural QSAR criteria, 23 due to overlap with 
training set 1 structures, 14 due to internal structural duplicates (two of these due to conflicting 
experimental results), and 74 due to inconclusive experimental results. When merging training set 1 
and the test set, which at this point was un-blinded to DTU Food, the experimental results of the 23 
structures removed from the test set due to overlap with training set 1 structures were compared 
with their corresponding training set 1 experimental results. In four cases the experimental results 
disagreed, and these structures were therefore removed from the final training set 2 (Table 1). 
The chemical structures in the provided datasets had undergone thorough quality control and 
curation [41,52]. In addition, since the datasets originated from the same source, i.e. U.S. EPA NCCT, 
and all chemicals had been screened in the same testing protocols and undergone the same data 
processing, this has likely contributed to decrease the experimental variability. The quality of the 
AUR-TPO assay has been assessed previously [34,39] and indicated excellent performance with 
robust Z-prime factor from 0.77 to 0.83, where values above 0.5 generally indicate excellent 
performance to distinguish between actives and inactives, and high intralaboratory repeatability 
with the robust coefficient of variance being 3–4%. The data in training set 1 and 2 and the test set 
where therefore assessed to be of high quality [34,39] and expected to be a good basis for QSAR 
model development. The AUR-TPO assay measures the fluorescence intensity from the commercial 
peroxidase substrate, Amplex®UltraRed (AUR), which is converted to Amplex UltroxRed by a 
peroxidase in the presence of hydrogen peroxide. A decrease in fluorescence intensity in response to 
a chemical is an indirect measure of TPO inhibition. The reaction chemistry and oxidation product of 
AUR is proprietary and the exact reaction(s) inhibited and its reversibility cannot be identified [34]. 
Therefore, the AUR-TPO assay read out has multiple potential confounders, including: non-specific 
enzyme inhibition; reactive, autofluorescent or fluorescence quenching chemicals; and other sources 
of interference with the peroxidase reaction [34,39]. When comparing results from the AUR-TPO 
assay with results from the lower throughput orthogonal guaiacol oxidation assay, the AUR-TPO 
  
16 
 
assay was previously found to have a sensitivity of 86% and a specificity of 39% [34]. Part of the high 
sensitivity of AUR-TPO could be due to a higher rate of false positive results from confounding non-
specific activity decrease, a known problem with loss-of signal assays. Identification and removal of 
such potentially AUR-TPO false positive TPO inhibitors in the datasets was attempted by the 
application of the selectivity score filter [34] and the inconclusive category, i.e. AUR-TPO positives 
with a selectivity score less than 1, see section 2.1. However, not all mechanisms potentially causing 
non-specific activity decrease, e.g. fluorescence quenching, have been addressed in the selectivity 
score [34] and so the presence of false positive TPO inhibitors in the training and test sets cannot be 
excluded. Furthermore, the tiered screening approach in AUR-TPO with a cutoff of 20% activity 
decrease in the initial single, high-concentration screening [34] may have produced some false 
negatives as it cannot be excluded that a portion of the chemicals causing an activity decrease below 
the 20% cutoff would have been positive if screened for concentration-response. In addition to the 
potential confounding effects in the raw experimental outputs, the models applied for the ‘hit-call’ 
assignment and the selectivity score algorithm are also subject to some degree of uncertainty in 
their results.  
3.2 QSAR Modeling and Selection 
Table 2 shows the LPDM cross-validation results for the seven models built from training set 1 and 2, 
respectively. As mentioned above, the LPDM cross-validation was used to guide relative 
performance-based selection between the seven preliminary models. As can be seen in Table 2, the 
composite modeling approaches 4 to 7 outperformed the single models 1, 2 and 3 in the LPDM 
cross-validation with regard to the balanced accuracy (Table 2). This is most likely an effect of the 
imbalanced distribution of actives and inactives in both training sets with a ratio of approximately 
1:6 (Table 1). The composite model feature in LDPM was implemented to handle such imbalanced 
training sets to include also a high proportion of the bigger class and thereby optimize the size of the 
AD [56].  
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In this work we employed a new approach where a single, unbalanced model (i.e., model 3) was 
added as a sub-model, together with the balanced sub-models from a composite model (i.e., model 
6), to form a new composite model (i.e., model 7). This addition caused a significant reduction in the 
number of false positive predictions (FPs) produced in the LPDM cross-validation as compared to 
model 6 alone (see Table 2). For both training set 1 and 2 this resulted in a remarkable increase in 
the LPDM cross-validation specificity while causing only a smaller reduction in sensitivity (Table 2), 
and together this explains why model 7, in both cases, outperformed the other composite models 4, 
5 and 6. To conclude, model 7 was the best performing among the seven models for both training 
set 1 and 2, and therefore selected for both training sets, and these models were named QSAR1 and 
QSAR2, respectively (Table 3). 
3.3 Predictive Performance of the QSAR Models 
The two selected and final models, QSAR1 and QSAR2, underwent a five times two-fold DTU Food in-
house cross-validation procedure to evaluate their predictive performance and robustness. QSAR1 
also underwent a DTU Food blinded external validation with the test set. The results from the 
validation studies are presented in Table 3 and demonstrate high predictive performance, i.e. 
balanced accuracies of 85.3% by external validation for QSAR1 and 82.7% by cross-validation for 
QSAR2, respectively.  
Adding the test set to training set 1 to build QSAR2 served multiple purposes. One purpose was to 
explore how much the added test set would enlarge the AD of the model and thereby increase the 
coverages of the two large chemical screening inventories, U.S. EPA and REACH-PRS. The coverage of 
QSAR2 was roughly 6% larger in the cross-validation (Table 3) and 10% larger for both screening 
inventories (Table 5) than the respective coverages of QSAR1. A second purpose of adding the test 
set in QSAR2 was to explore the possible improvements in predictive performance. To do this, we 
first built the smaller QSAR1 model and performed both a rigorous five times two-fold cross-
validation procedure and an external validation with the test set. As can be seen in Table 3 the 
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validation procedures show that QSAR1 has high predictive performance and is a robust model, i.e. a 
balanced accuracy of 85.3% in external validation and 80.6% with an SD of 4.6% in the cross-
validation. A comparison of the statistical parameters from the two validation methods indicates 
that the rigorous cross-validation procedure applied does not overestimate the model’s predictive 
performance, but rather, outputs conservative estimates. This conservative nature of the cross-
validation is likely due to the rigorous procedure of removing 50% of the full training set to build the 
cross-validation models. Such a procedure is especially hard on the proportionally few actives in 
training set 1, i.e. 130 out of 877 (Table 1), which is also reflected in the relatively high SD of 10% in 
the sensitivity of the ten QSAR1 cross-validation models (Table 3) as well as its lower mean value 
(72.3%) compared to the sensitivity from the external validation (79.7%). The structures in the test 
set used for the DTU-blinded external validation of QSAR1 were not selected due to specific TPO 
inhibition concerns or to serve as a representative test set for QSAR1, but instead selected because 
they are included in the U.S. EPA regulatory ToxCast universe based on potential for exposure, and 
not because of prior concern about endocrine disruptive effects [41,42].  
The procedure of performing both independent and robust cross-validation and a large, 
representative and prospective external validation is optimal when evaluating a model’s predictive 
performance, but external validation has the disadvantage of withholding what may in many cases 
be valuable data from the model itself [43,59]. Adding all available data to a training set can, in 
addition to expanding the AD, also result in a model with a higher predictive performance, 
depending on the characteristics of the added data. The QSAR2 model could not undergo an 
external validation procedure due to lack of another external test set. Previous studies have shown 
that robust cross-validations give reliable estimates of a model’s predictive performance (e.g. 
[59,60]). For QSAR1, the applied two-fold cross-validation procedure gave a conservative measure of 
performance in comparison to the external validation. Based on this, we anticipate that QSAR2 will 
have a similar or higher predictive performance if it underwent a robust external validation with a 
test set generated using the same protocol and data processing. As can be seen from Table 3, the 
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cross-validation sensitivity was slightly increased in QSAR2 (75.6%) compared to QSAR1 (72.3%) and 
the sensitivity SD was reduced from 10.1% to 5%. This is most likely the effect of an increase in 
actives from 130 in training set 1 to 230 in training set 2, which renders the 50% exclusion in the 
cross-validation procedure less influential on the sensitivity. As there were already many inactives in 
training set 1, the addition of more inactives to training set 2 did, as expected, not have the same 
high impact on the specificity, which went from 89.0% (SD 2.8%) in QSAR 1 to 89.8% (SD 1.5%) in 
QSAR2.  
3.4 Top Structural Features in QSAR2 
The ten most frequent and discriminating predictive structural features associated with actives and 
inactives, respectively, in QSAR2 are shown in Figure 3. Among the highest ranking structural 
features associated with activity were versions of phenols, anisole and aniline. The most frequent 
structural features associated with inactivity included ethers, esters, aryl halides and a tertiary 
amine. To our knowledge structural docking or pharmacophore studies for TPO have not been 
performed (Simmons et al., in prep). 
3.5 The Screening Results 
We found a total of 27,444 substances present in both the U.S. EPA and the full REACH-PRS 
inventories. There were 19,279 unique structures in common in the two inventories (Table 4). To our 
knowledge this is the first study that has quantified the overlap between these two inventories, both 
with regard to overall substance and unique structure overlap. The high overlap between the U.S. 
EPA set and the REACH-PRS set was not surprising since both inventories represent collections of 
man-made, environmental chemicals in the U.S. and EU, respectively.  
Both the U.S. EPA and REACH-PRS inventories were screened using QSAR1 and QSAR2 for TPO 
inhibition. In Table 5 the coverage of the two substance inventories, i.e. the proportion of the full set 
predicted within the AD of the model, and the number of active and inactive predictions are 
presented for each model. As expected, the coverage of QSAR2 was larger than QSAR1 of both 
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screening sets. The percentage of chemicals in the two inventories with active predictions in the AD 
of the two models ranged from 16.5% to 19.3% (Table 5). Although slightly higher this is not very 
different from the percentage of experimentally determined actives of 14.8% to 15.5% in the 
training and test sets (Table 1). As mentioned earlier, the chemicals in the experimental datasets 
were not selected on the basis of expected TPO inhibition effects. It is not known to what extent the 
slightly higher percentages of TPO inhibitors in the two predicted screening sets are due to false 
positive predictions or if they reflect a true TPO inhibitor prevalence. The validation studies showed 
that both QSAR1 and QSAR2 have specificities >10% higher than their respective sensitivities (Table 
3), and therefore both models are expected to, in a balanced universe, make relatively more false 
negative than false positive predictions.  
3.6 Butylated Hydroxyanisole as a Potential Thyroid Hormone Disruptor 
We searched the two chemical inventories for possible examples of human-relevant chemicals with 
known indications for adverse neurodevelopmental outcomes. Included in both the U.S. EPA and the 
REACH-PRS set were the two isomers of butylated hydroxyanisole (BHA, CASN 25013-16-5), 2-tert-
Butyl-4-hydroxyanisole (2-BHA, CASN 88-32-4) and 3-tert-Butyl-4-hydroxyanisole (3-BHA, CASN 121-
00-6) (Figure 4). BHA is manufactured and/or imported to the EU in a total of 100-1,000 tonnes per 
year and is used as an antioxidant and preservative in e.g. food, food contact materials, cosmetics, 
and pharmaceuticals [61–63]. It is an anticipated human carcinogen [64] and is has been noted to 
have published evidence of developmental neurotoxicity (DNT) in mammals [65,66]. Both in vitro 
and in vivo published studies indicate that the BHA isomers have endocrine-modulating potential, 
with most evidence for estrogenic and androgenic effects [63,67–72]. Based on this, BHA is on both 
the EU list of potential endocrine disruptors [73,74] and on the SIN (Substitute It Now!) List [75,76]. 
However, more data is needed to fully elucidate BHA’s potential as an endocrine disruptor and its 
mode of action(s) in DNT [63].  
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Both 2- and 3-BHA were predicted active for TPO inhibition by QSAR2, and 3-BHA was included in 
the QSAR2 training set as a TPO inhibitor. Studies in rats and pigs indicate that exposure to BHA 
(mixture of the two isomers) in utero can cause effects such as changed thyroxine serum levels, 
altered thyroid gland function and histology, and altered brain weight and behavior in the offspring 
[66,67,72]. TPO inhibition is as mentioned above identified to be the MIE in an AOP for thyroid-
related neurodevelopmental adverse effects (under development) [41]. The three common top 
activity-associated structural features from QSAR2 in the two isomers were identified as described in 
section 2.6 and is shown in Figure 4. Two of the features, “Scaffold 297” and “benzene, 1-alkoxy-,4-
hydroxy” were among the top ten structural features associated with activity in QSAR2 (Figure 3). 
“Scaffold 297” was present in eleven training set 2 structures of which nine were experimentally 
active for TPO inhibition. The “benzene, 1-alkoxy-,4-hydroxy” structural feature was present in five 
training set 2 structures that were all experimentally positive.  
The QSAR2 training set including flags for the test set structures of QSAR1 as well as the full 
experimental  background data set used to prepare the QSAR sets are available for download at the 
following link: http://qsar.food.dtu.dk/download/TPO_inhibition_QSAR_training_set.zip. Work is 
underway to make the training sets available from the U.S. EPA ToxCast website. Furthermore, 
predictions for around 640,000 structures in QSAR2, including the 72,524 REACH-PRS structures, will 
be made available from the online Danish (Q)SAR Database [46]. QSAR2 will also be made available 
for prediction of user-submitted structures in a coming free online Danish (Q)SAR Models sister-site 
to the Danish (Q)SAR database at the DTU homepage [46].  
4. Conclusions 
The present study reports the development, validation, and application of two global, binary 
composite QSAR models for TPO inhibition in vitro. The first model, QSAR1, showed high predictive 
performance in both cross-and external validation with balanced accuracies of 80.6% (SD = 4.6%) 
and 85.3%, respectively. QSAR2, the second model, enlarged with the external test set of QSAR1, 
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showed improved robustness and predictive performance in cross-validation compared to QSAR1, 
i.e. a balanced accuracy of 82.7% (SD = 2.2%), and this was largely driven by an increase in sensitivity 
from 72.3% (SD = 10.1%) of QSAR1 to 75.6% (SD 5.0%) of QSAR2. The top-10 structural features in 
QSAR2 related to TPO enzyme inhibition and non-inhibition, respectively, were identified. The two 
QSAR models were used to screen two large chemical inventories from the U.S. and EU containing 
structurally diverse man-made chemicals to which humans are potentially exposed. QSAR2 showed 
an increase in coverage of ~10% for both inventories relative to QSAR1, and of the substances 
predicted within QSAR2’s AD, 8,790 (19.3%) REACH-PRS substances and 7,166 (19.0%) U.S. EPA 
substances, respectively, were predicted to be TPO inhibitors. Among the predicted TPO inhibitors 
were the two isomers of BHA, which have previously been shown to cause both TH and neurological 
effects in animal studies. These QSAR predictions may contribute to elucidating the mode of action 
by which BHA results in these altered TH levels and neurological adverse outcomes. Overall, 
predictions from the two models can be used to prioritize chemicals for further testing and in 
considerations of possible concerns for downstream adverse outcomes (e.g., DNT) [77,78]. They may 
also be used e.g. in read-across cases or in IATA WoE assessments.  
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Tables and Figures 
 
Table 1. Number of structures in the QSAR-ready training sets 1 and 2, and test set with the distribution of 
active and inactive experimental results for TPO inhibition. 
Datasets Total number of unique structures Active (%) Inactive (%) 
Training set 1 877 130 (14.8) 747 (85.2) 
Test set* 646 100 (15.5) 546 (84.5) 
Training set 2** 1519 230 (15.1) 1289 (84.9) 
*The experimental results of the test set were masked to DTU Food model developers until after being predicted in QSAR1.  
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** some of the training set 1 structures were tested again together with the test set structures, and of these four structures had different 
activities compared to the training set 1 activity. The three training set 1 structures were removed from training set 2.  
 
Table 2. The results from the LPDM cross-validation of the seven built models from training set 1 and 2, 
respectively. 
Model  LPDMs 10 times two-fold cross-validation results 
Training set 1 
Sensitivity 
(%) 
Specificity 
(%) 
Balanced accuracy 
(%) 
TP* FP* TN* FN* 
1 43.0 96.8 69.9 49 21 626 65 
2 48.2 96.0 72.1 55 26 621 59 
3 50.0 96.3 73.2 57 24 623 57 
4 72.9 82.7 77.8 94 105 502 35 
5 81.4 78.2 79.8 105 136 498 24 
6 84.5 80.3 82.4 109 123 502 20 
7 74.6 92.5 83.6 97 55 676 33 
Training set 2 
Sensitivity 
(%) 
Specificity 
(%) 
Balanced accuracy 
(%) 
TP* FP* TN* FN* 
1 46.5 96.9 71.2 99 40 1153 114 
2 49.8 96.1 73.0 106 46 1147 107 
3 46.5 96.7 71.6 99 39 1154 114 
4 79.1 79.9 79.5 182 233 928 48 
5 75.7 79.5 77.6 174 240 931 56 
6 76.1 78.4 77.3 175 253 918 55 
7 71.3 92.6 82.0 164 95 1187 66 
*TP: true positives, FP: false positives, TN: true negatives, FN: false negatives. The numbers are averages of the ten iterations as given by 
LPDM. 
 
Table 3. Modeling approach applied and the predictive performances for QSAR1 and QSAR2. 
Model Statistical Parameter Cross-Validation*, % 
(SD, %) 
External Validation**, % 
(actual numbers) 
QSAR1 
Approach 7 
Sub-models: 7 
Sensitivity 72.3 (10.1) 79.7 (47/(47 + 12)) 
Specificity 89.0 (2.8) 90.8 (266/(266 + 27)) 
Balanced accuracy 80.6 (4.6) 85.3 ((79.7 + 90.8)/2) 
Coverage 51.6 (4.7) 54.5 (352/646) 
QSAR2 
Approach 7 
Sub-models: 7 
Sensitivity 75.6 (5.0) - 
Specificity 89.8 (1.5) - 
Balanced accuracy 82.7 (2.2) - 
Coverage 57.8 (5.4) - 
*A five times two-fold cross-validation, ** A blinded external validation with the experimental results of the test set being masked to the 
model developers at DTU Food. 
 
Table 4. The overlap in substances and unique structures between the U.S. EPA and REACH-PRS inventories.  
Overlap analysis U.S. 
EPA* 
REACH-
PRS** 
Total 
number 
In common Unique to a set 
REACH-PRS 
in U.S. EPA 
U.S. EPA in 
REACH-PRS 
REACH-
PRS 
U.S. 
EPA 
Structure entries 32,197 72,524 104,721 27,444 19,279 45,080 12,918 
Unique structures 32,197 60,281 92,478 19,279 19,279 41,002 12,918 
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*U.S. EPA: QSAR-ready structures from an U.S. EPA selected inventory of man-made chemical structures to which humans are potentially 
exposed, ** REACH-PRS: QSAR-ready structures from the REACH pre-registered substances list 
 
Table 5. The coverage (AD) and the number of active/inactive predictions of the U.S. EPA and REACH-PRS 
inventories in QSAR1 and QSAR2. 
 Total QSAR 1 QSAR2 
  In AD (%) Active (%) Inactive (%) In AD (%) Active (%) Inactive (%) 
U.S. 
EPA* 
32,197 16,898 (52.5) 
2855 
(16.9) 
14,043 
(83.1) 
19,392 
(60.2) 
3201 
(16.5) 
16,191 
(83.5) 
REACH-
PRS** 
72,524 38,661 (53.3) 
7,128 
(18.4) 
31,533 
(81.6) 
45,540 
(62.8) 
8,790 
(19.3) 
36,750 
(80.7) 
REACH-
PRS 
unique 
60,281 32,334 (53.6) 
5,879 
(18.2) 
26,455 
(81.8) 
37,784 
(62.7) 
7,166 
(19.0) 
30,618 
(81.0) 
*U.S. EPA: QSAR-ready structures from an U.S. EPA selected inventory of man-made chemical structures to which humans are potentially 
exposed, ** REACH-PRS: QSAR-ready structures from the REACH pre-registered substances list 
 
 
Figure 1. An overview of the dataset preparation procedure. S-C, single concentration screening; C-R, 
concentration response screening. *The experimental results of the dataset were blinded to the modelers at 
DTU Food 
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Figure 2. An overview of the datasets, modeling, structural feature sorting and screening.   is the mean TPO 
inhibition experimental activity and n is the number of training set structures.  
* The experimental results of the dataset were blinded to the modelers at DTU Food until after external 
validation had been performed. 
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Figure 2. The structural features used in QSAR2 were sorted on |0.5 -   (TPO inhibition activity)|∙ n, and the ten 
most frequent and discriminating structural features alerting for activity(  (TPO inhibition activity) > 0.8) and 
inactivity (  (TPO inhibition activity) < 0.02) are shown here. Ak matches saturated carbon and X matches the 
halogen atoms Cl, Br, I or F. Numbers in the upper left corners display the ratio of TPO inhibitors/non-
inhibitors in training set 2 for the specific structural feature. 
 
 
 
 
 
 
 
 
Figure 3. The two isomers of BHA and the three predictive structural features alerting for activity in QSAR2 
selected based on highest |0.5 –   (TPO inhibition activity)|*n and an   > 0.8. *3-BHA (CASN 121-00-6) was 
included in the training set and is the closest analog to 2-BHA (CASN 88-32-4). 
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Highlights: QSAR Models for Thyroperoxidase Inhibition and Screening of U.S. and EU Chemical 
Inventories 
 Development of two QSAR models for TPO inhibition 
 Highly performing and robust models according to cross- and external validations 
 Predictions of two large U.S. and EU chemical inventories for TPO inhibition 
 Identification of structural features associated with TPO inhibition 
 
 
